Zomedica Q1 net loss narrows to $4.5 million; revenue rises 35% to $8.8 million

Zomedica Corp.

Zomedica Corp.

ZOMDF

0.00
  • Zomedica posted first-quarter revenue of $8.8 million, up 35% year over year, marking its first time above $8 million for the period.
  • Net loss narrowed to $4.5 million; gross margin was 62%.
  • Diagnostics segment revenue climbed 73% to $1 million, while Therapeutic Device segment revenue was $5.8 million.
  • Cash burn fell 15% to $5.7 million; liquidity totaled $47.5 million as of March 31, 2026.
  • Business updates included January launch of AI-enabled TRUVIEW digital microscopy and telepathology platform, February distribution agreement with Moichor, and March collaboration with Boehringer Ingelheim Animal Health to support equine PPID testing using TRUFORMA assays.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zomedica Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-004419), on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.